MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1002/14651858.cd008588.pub2

Медицинская библиотека · The Cochrane database of systematic reviews · 2013

Chemotherapy for thymic carcinoma and advanced thymoma in adults.

Wei Mao Ling, Kang Deying, Gu Lijia, Qiu Meng, Zhengyin Liao, Mu Yanming

СтатьяПоддержка исследования: вне правительства СШАСистематический обзорПеревод пока не подготовлен

Аннотация

BACKGROUND

Thymic carcinoma or advanced thymoma is a rare cancer of the thymus gland that tends to be aggressive and infiltrate neighbouring organs, making total resection very difficult. Induction or adjuvant chemotherapy, or both, are often used in a multimodality approach to treat people affected by this condition, but the effectiveness of chemotherapy for thymic carcinoma or advanced thymoma remains uncertain.

OBJECTIVES

To assess the role of chemotherapy in adults with thymic carcinoma or advanced thymoma.

SEARCH

METHODS

We searched the Cochrane Central Register of Controlled Trials (CENTRAL 2012, Issue 7), MEDLINE (accessed via Ovid from 1966 to July 2012), EMBASE (accessed via Ovid, from 1980 to July 2012), Latin American and Caribbean Literature on Health Sciences (LILACS), the Chinese Biological Medicine Database (CBM, 1978 to July 2012), China National Knowledge Infrastructure (CNKI, 1980 to July 2012) and the Chinese scientific periodical database VIP Information (VIP, 1989 to July 2012). There was no language restriction in searching for studies.

SELECTION CRITERIA: We planned to include randomised controlled trials (RCTs) of  trials using chemotherapy (either single-agent or combination chemotherapy plus surgery, radiotherapy or not) for thymic carcinoma and/or advanced thymoma. We planned to include all adults (aged 18 years and over) diagnosed with thymic carcinoma and/or with Masaoka stage III or IV thymic tumours. The intended primary outcomes were overall survival (OS) and progression-free survival (PFS).

DATA COLLECTION AND ANALYSIS: Two review authors independently evaluated the search results according to the inclusion and exclusion criteria. There were no studies identified for inclusion and therefore no data extraction was completed.

MAIN

RESULTS

No RCTs were eligible for inclusion in this review. We report details of excluded prospective studies in an additional table and try to provide some useful evidence regarding current practice.

AUTHORS'

CONCLUSIONS

There were no RCTs eligible for inclusion in this review. In current practice the most common regimen for adult patients with thymic carcinoma or advanced thymoma is cisplatin-based chemotherapy. Considering the condition is rare, it is suggested that an international group is set up to organise and evaluate prospective collection of data from cohorts of patients to inform current clinical practice.

Для цитирования: Wei Mao Ling, Kang Deying, Gu Lijia, Qiu Meng, Zhengyin Liao, Mu Yanming. Chemotherapy for thymic carcinoma and advanced thymoma in adults.. The Cochrane database of systematic reviews. 2013. DOI: 10.1002/14651858.cd008588.pub2.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.